---
schema_version: "secwatch.filing_event.v1"
accession: "0001753926-25-001768"
form_type: "8-K"
ticker: "VANI"
cik: "0001266806"
company_name: "Vivani Medical, Inc."
filed_at: "2025-11-13T23:59:59+00:00"
generated_at: "2026-05-16T20:09:15.966479+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Vivani Medical Q3 net loss $6.5M; plans Phase 1 semaglutide implant study in H1 2026

## Summary
- Net loss of $6.5M in Q3 2025 vs $6.0M in Q3 2024; cash down to $4.0M from $19.7M at year-end 2024.
- Closed ~$15.7M in October equity financings and $10M August private placement, total $25.7M cash and commitments.
- Plans to initiate Phase 1 clinical study of NPM-139 semaglutide implant for chronic weight management in first half 2026.
- Spin-off of Cortigent temporarily withdrawn due to U.S. government shutdown; new record date expected after SEC resumes.
- R&D expense $4.5M ($4.2M in Q3 2024); G&A $2.2M ($2.1M in Q3 2024); operating expenses increased $0.4M.

## SEC filing metadata
- accession: 0001753926-25-001768
- form_type: 8-K
- ticker: VANI
- cik: 0001266806
- company_name: Vivani Medical, Inc.
- filed_at: 2025-11-13T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1266806/000175392625001768/0001753926-25-001768-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1266806/000175392625001768/vani-20251113.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001753926-25-001768
- JSON: https://secwatch.observer/filing/0001753926-25-001768.json
- Plain text: https://secwatch.observer/filing/0001753926-25-001768.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.